Abstract
This systematic review evaluates the prevalence of long-term complications of serogroup B meningococcal disease (MD) in light of the recent licensure of a vaccine against meningococcal B disease. Twelve appropriate studies were identified by searching available databases from 1946 to July 2014. The average prevalence of hearing impairment was 4.2% among serogroup B MD survivors; 2.3% suffered amputation and 2.3% developed seizures. When compared with complications due to non-meningococcal B bacterial meningitis, physical impairment and seizures were more common in survivors of meningococcal B disease but hearing impairment had similar prevalence. Few studies quantified less frequent complications such as visual impairment and cognitive dysfunction. Better comprehensive reporting of the complications and costs of serogroup B MD in survivors and their families is needed to inform vaccination policy.
Keywords: Complications, meningococcal disease, serogroup B.
Infectious Disorders - Drug Targets
Title:Complications of Serogroup B Meningococcal Disease in Survivors: A Review
Volume: 14 Issue: 3
Author(s): Fereshteh Dastouri, Ahmad Mirmohammad Hosseini, Elizabeth Haworth, Gulam Khandaker, Harunor Rashid and Robert Booy
Affiliation:
Keywords: Complications, meningococcal disease, serogroup B.
Abstract: This systematic review evaluates the prevalence of long-term complications of serogroup B meningococcal disease (MD) in light of the recent licensure of a vaccine against meningococcal B disease. Twelve appropriate studies were identified by searching available databases from 1946 to July 2014. The average prevalence of hearing impairment was 4.2% among serogroup B MD survivors; 2.3% suffered amputation and 2.3% developed seizures. When compared with complications due to non-meningococcal B bacterial meningitis, physical impairment and seizures were more common in survivors of meningococcal B disease but hearing impairment had similar prevalence. Few studies quantified less frequent complications such as visual impairment and cognitive dysfunction. Better comprehensive reporting of the complications and costs of serogroup B MD in survivors and their families is needed to inform vaccination policy.
Export Options
About this article
Cite this article as:
Dastouri Fereshteh, Mirmohammad Hosseini Ahmad, Haworth Elizabeth, Khandaker Gulam, Rashid Harunor and Booy Robert, Complications of Serogroup B Meningococcal Disease in Survivors: A Review, Infectious Disorders - Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871526515999150320155614
DOI https://dx.doi.org/10.2174/1871526515999150320155614 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Reactions of Hydrazones with Lead Tetraacetate in Organic Synthesis
Current Organic Chemistry Possible Protecting Role of TNF-α in Kainic Acid-induced Neurotoxicity Via Down-Regulation of NFκB Signaling Pathway
Current Alzheimer Research Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review
Current Cardiology Reviews Activation of Latent HIV-1 Expression by Protein Kinase C Agonists. A Novel Therapeutic Approach to Eradicate HIV-1 Reservoirs
Current Drug Targets Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Cannabinoid Signaling in Glial Cells in Health and Disease
Current Neuropharmacology Clinical Application of Ropivacaine for the Lower Extremity
Current Topics in Medicinal Chemistry New and Promising Chemotherapeutics for Emerging Infections Involving Drug-resistant Non-albicans Candida Species
Current Topics in Medicinal Chemistry Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry Antiretroviral and Antituberculosis Therapy in HIV-TB Co-Infected Children
Current Pediatric Reviews Pulmonary Cryptococcocal Infection
Current Respiratory Medicine Reviews Overview of Congenital Infections: The Prominence of Cytomegalovirus
Infectious Disorders - Drug Targets Modulation of the Human Gut Microflora Towards Improved Health Using Prebiotics - Assessment of Efficacy
Current Pharmaceutical Design The Molecular Basis of Susceptibility to Infection in Liver Cirrhosis
Current Medicinal Chemistry Currently Used Biologic Agents in the Management of Behcet’s Syndrome
Current Medicinal Chemistry Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets Towards Retinoid Therapy for Alzheimers Disease
Current Alzheimer Research